Recent IRadimed News
Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.
Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026.
Orlando, Florida, April 10, 2026 – Iradimed Corporation (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.
Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 25th Annual Needham Virtual Healthcare Conference, which is scheduled to take place from April 13-16, 2026.
Orlando, Florida, March 16, 2026 – IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38th Annual Roth Conference.
Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024.
Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025, which are increases of 25% and 23%, respectively, compared to the same period in 2024.
Reports record GAAP diluted EPS of $1.75 and non-GAAP diluted EPS of $1.93 for the full year of 2025, which are increases of 17% and 16%, respectively, compared to the full year of 2024.
Declares a regular quarterly cash dividend of $0.20 per share of common stock for the fourth quarter of 2025, payable on March 6, 2026.
Orlando, Florida, December 8, 2025 – IRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025.
IRADIMED CORPORATION announced its selection to TIME's prestigious list of America's Growth Leaders for 2026. This marks the Company's recognition among the top U.S. companies demonstrating outstanding growth, as determined by TIME and Statista.
Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.
Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.
Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.
Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025.
Orlando, Florida, September 2, 2025 – IRADIMED CORPORATION (“Iradimed” or the “Company”) (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”)-compatible patient monitoring and infusion systems, today announced a Board of Directors (the “Board”) transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after deciding it is time to step away following many years of dedicated service. Effective September 2, 2025, the Board has appointed Joe Kiani, Masimo founder and renowned medical technology innovator and entrepreneur, to fill the vacancy on the Board.
Orlando, Florida, August 26, 2025 – IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and infusion systems, today announced that it will participate in the Wells Fargo 2025 Healthcare Conference, held September 3-5, 2025, in Boston, Massachusetts.
Roger Susi, President and CEO, and Jack Glenn, CFO, will host 1x1 investor meetings at the 2025 Wells Fargo Healthcare Conference on September 4, 2025, in Boston, MA.
Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.
Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.
Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025.
Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System.
Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.
Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.
Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025.
Winter Springs, Florida, March 10, 2025 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37th Annual Roth Conference.
Iradimed’s CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on-one meetings between company management and investors at the 37th Annual Roth Conference, which will be held at the Laguna Cliffs Marriott in Dana Point, CA, on March 17 and 18, 2025.
Reports record revenue of $19.4 million for the fourth quarter of 2024, an increase of $1.9 million or 11%, compared to the same period in 2023.
Reports GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44 for the fourth quarter of 2024.
Reports GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66 for the full year of 2024.
Declares a regular quarterly cash dividend of $0.17 per common share for the first quarter of 2025, payable on March 5, 2025.
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million
Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million
Iradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT
Winter Springs, Florida, December 19, 2024 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference.
The Company presentation will take place on Wednesday, January 15, 2025, at 5:15 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Events and Presentations” section of the Company’s investor website at: https://www.iradimed.com/investors/events.
Winter Springs, Florida, October 3, 2024 – IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference.
Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on October 9, 2024.
Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.1 percent over the comparable period 2023.
Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.
Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023.
Declares a regular quarterly cash dividend of $0.15 per common share for the third quarter of 2024, payable on August 30, 2024.
Iradimed announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.” Stockholders are not required to take any action due to the uplisting.
Reports record revenue of $17.6 million for the first quarter of 2024.
Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.
Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.
Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024.
• Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023.
• Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023.
• Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023.
• Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022 and full-year operating income of $20.0 million, an increase of 28.2%, compared to the same period in 2022.
Winter Springs, Florida, January 2, 2024 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.
Iradimed’s CEO, Roger Susi, is scheduled to present on Thursday, January 11, 2024, at 12:00 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Events and Presentations” section of the Company’s investor website at https://www.iradimed.com/investors/events.
Winter Springs, Florida, December 12, 2023 – IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023.
IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named on Forbes’ latest list of America’s Most Successful Small-Cap Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
Reports record revenue of $16.5 million for the third quarter of 2023.
GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.
Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022.
Winter Springs, Florida, September 6, 2023 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences.
Reports record revenue of $16.1 million for the second quarter of 2023
GAAP diluted EPS of $0.33 and non-GAAP diluted EPS of $0.36
Operating income was $5.0 million and increased by 19%
Announces third quarter and full year 2023 financial guidance
Winter Springs, Florida, May 10, 2023 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), was recently named on Forbes’ latest list of America’s Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a nonmagnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
Reports record revenue of $15.5 million for the first-quarter quarter of 2023
GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30
Operating income was $4.0 million and increased by 30%
Announces second quarter 2023 financial guidance and increases full-year 2023 financial guidance